Synthetic Biologics, Inc. (NYSEMKT:SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced that in view of the unusual market activity in the Company’s stock, the NYSE MKT (the “Exchange”) has contacted the Company in accordance with its usual practice. The Company stated that its policy is not to comment on unusual market activity. Synthetic Biologics Inc (NYSEMKT:SYN) stock opened at $2.49 in last trading session, and closed at $2.44, trading in the range of $2.32 – $2.80. The stock showed a positive weekly performance of 29.10%.
Oncothyreon Inc (USA) (NASDAQ:ONTY) average recommendation is overweight with average Target Price of $4.20. Oncothyreon Inc (USA) (NASDAQ:ONTY) shares closed at $2.79 on last trade day, by gaining -1.06%. Stock 52 week range is $1.55 – $3.08. Company’s market capitalization is $193.39 million.
Deutsche Bank raised their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $125.00 to $205.00 in a research note issued on Monday, Analyst Ratings News reports. The firm currently has a “buy” rating on the stock. Deutsche Bank’s price objective indicates a potential upside of 17.53% from the company’s current price. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) stock advanced 0.31% and finished the last session at $180.55. The EPS of the stock remained 1.27. Company’s market capitalization is $35.72 billion.
Illumina (NASDAQ:ILMN) CEO Jay T. Flatley sold 30,000 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $160.43, for a total value of $4,812,900.00. Following the sale, the chief executive officer now directly owns 385,105 shares of the company’s stock, valued at approximately $61,782,395. Illumina, Inc. (NASDAQ:ILMN) stock opened at $162.85 in last trading session and closed at $164.33. The 52 week range of the stock is $48.00 – $165.45 and the day range was $161.00 – $165.45.